Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at Upcoming Scientific Mee

Before you go, we thought you'd like these...
Before you go close icon

Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek®Data at Upcoming Scientific Meetings in October

-Data from Lymphoseek studies to be presented at the American Association of Pharmaceutical Scientists, the European Association of Nuclear Medicine and the American Society for Radiation Oncology Conferences -

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Lymphoseek studies in breast cancer and melanoma are being presented during the month of October at the American Association of Pharmaceutical Scientists meeting in Chicago, IL, the European Association of Nuclear Medicine conference in Milan, Italy and the American Society for Radiation Oncology meeting in Boston, MA. Details of the presentations and posters are listed below.

Conference: 

American Association of Pharmaceutical Scientists

Date:October 14-18, 2012
Location:Chicago, IL
 
Poster Title 1:

The Effect of Post-Injection Time Interval of Tc 99m Tilmanocept Injection to In Vivo Probing on Nodal Concordance Rates Relative to Vital Blue Dye in Melanoma and Breast Cancer Patients Undergoing Intraoperative Lymphatic Mapping

Author:Frederick Cope, PhD, Navidea Biopharmaceuticals
Session, Date:Poster Sessions
 
Poster Title 2:

Sensitivities and False Negative Rates of Tc 99m Tilmanocept and Vital Blue Dye By Time Interval of Tc 99m Tilmanocept Injection to In Vivo Probing in Melanoma and Breast Cancer Patients Undergoing Intraoperative Lymphatic Mapping

Author:Wendy L. Metz, PhD, Navidea Biopharmaceuticals
Session, Date:Poster Sessions
 
Conference:

European Association of Nuclear Medicine

Date:October 27-31, 2012
Location:Milan, Italy
 
Presentation Title 1:

Phase 3 Trials Evaluating Biotargeted (CD206) Tc 99m Tilmanocept Against Vital Blue Dye (VBD) in the Detection of Lymph Nodes (LNs) in Breast Cancer (BC) Patients

Author:Frederick Cope, PhD, Navidea Biopharmaceuticals
Session, Date:Oncology Clinical Science: Sentinel Lymph Node 2 Session
Sunday, October 28, 2012
 
Presentation Title 2:

Clinical Performance of Tc 99m Tilmanocept Versus Vital Blue Dye (VBD) in the Detection of Lymph Nodes (LNs) in Melanoma Patients

Author:Frederick Cope, PhD, Navidea Biopharmaceuticals
Session, Date:Oncology Clinical Science: Sentinel Lymph Node 1 Session
Sunday, October 28, 2012
 
Conference:

American Society for Radiation Oncology (ASTRO)

Date:October 28-31, 2012
Location:Boston, MA
 
Poster Title:

Exploitation Targeting Of The CD206 Receptor In Lymph Node-Resident Reticuloendothelial Cells With A Novel Synthetic 99mTc-ligand (Tilmanocept) Significantly Enhances Localization In Contrast To 99mTc-Colloid: A New Meta-analysis

Author:Frederick Cope, PhD, Navidea Biopharmaceuticals
Session, Date:Poster Sessions

About Lymphoseek®

Lymphoseek® (technetium Tc 99m tilmanocept) Injection is a novel, receptor-targeted, small-molecule, investigational radiopharmaceutical used in lymphatic mapping procedures that are performed to help stage breast cancer and melanoma. Lymphoseek is designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer, in patients with breast cancer or melanoma.

Lymphatic mapping is a procedure in which lymph nodes that may contain tumor metastases are identified and biopsied to determine if cancer has spread beyond the primary tumor. Accurate staging of cancer is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. According to the American Cancer Society, approximately 229,000 new cases of breast cancer and 76,000 new cases of melanoma are expected to be diagnosed in the United States in 2012.

About Lymphatic Mapping

Lymphatic mapping is a procedure designed to guide lymph node dissection and biopsy procedures. It consists of Intraoperative Lymphatic Mapping (ILM) often accompanied by lymphoscintigraphy. Lymphoscintigraphy is an imaging procedure routinely performed pre-operatively to provide guidance on the location of lymph nodes to be biopsied. ILM is a surgical procedure in which lymph nodes draining the area around a tumor are identified and biopsied to determine if cancer has spread to the lymph nodes. These nodes, commonly referred to as "Sentinel Lymph Nodes," are removed and analyzed for the presence of malignant cells. Lymphatic Mapping provides an accurate staging procedure that can help ensure optimal surgical and therapeutic choices, including the avoidance of the morbidity of a complete lymph node dissection for patients in whom the Sentinel Lymph Nodes were found to be free of cancer.

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms - Lymphoseek®, NAV4694, CFT and RIGScanTM - to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements within the meaning of the Act. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.



Navidea Biopharmaceuticals, Inc.
Brent Larson, Sr. VP & CFO, 614-822-2330

KEYWORDS:   United States  North America  Ohio

INDUSTRY KEYWORDS:

The article Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at Upcoming Scientific Meetings in October originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners